Biote (BTMD) Ending Cash Position: $5.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BTMD Biote Corp BTMD
70 GF Score
Price $2.28
GF Value $3.06
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Biote Ending Cash Position?

Biote BTMD +2.69% 70 Ending Cash Position is $5.3 Mil as of Mar. 2026. GuruFocus rates BTMD with a GF Score™ of 70/100 and a GF Value™ of $3.06 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Biote's Ending Cash Position for the quarter that ended in Mar. 2026 was $5.3 Mil.

Biote's quarterly Ending Cash Position declined from Sep. 2025 ($28.0 Mil) to Dec. 2025 ($24.1 Mil) and declined from Dec. 2025 ($24.1 Mil) to Mar. 2026 ($5.3 Mil).

Biote's annual Ending Cash Position declined from Dec. 2023 ($89.0 Mil) to Dec. 2024 ($39.3 Mil) and declined from Dec. 2024 ($39.3 Mil) to Dec. 2025 ($24.1 Mil).

Biote Ending Cash Position Related Terms

Biote Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Biote's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biote Ending Cash Position Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 26.77 79.23 89.00 39.34 24.12

Biote Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.70 19.60 28.05 24.12 5.32
BTMD
70GF Score
Biote Corp BTMD
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biote Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Biote's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=39.342+-15.219
=24.1

Biote's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=24.123+-18.803
=5.3

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $5.3 Mil mean?
Biote (BTMD) has a Ending Cash Position of $5.3 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Biote and its competitors.
Is Biote's Ending Cash Position too high?
Biote's current Ending Cash Position is $5.3 Mil. Overall, Biote has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Ending Cash Position compare to DCGO and PARK?
Biote's Ending Cash Position of $5.3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Healthcare Providers & Services company?
A good Ending Cash Position depends on the Healthcare Providers & Services industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Biote and its competitors. Biote's current Ending Cash Position is $5.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.06, compared to a current price of $2.28 — trading 25.5% below its estimated fair value. The current Ending Cash Position is $5.3 Mil. Biote's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Biote (BTMD), the current Ending Cash Position is $5.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biote (BTMD) Overvalued in 2026?

Based on GuruFocus' analysis, Biote stock appears to be undervalued. The current stock price of $2.28 is trading 25.5% below its estimated GF Value™ of $3.06. GuruFocus considers Biote to be Modestly Undervalued.

Key valuation signals for BTMD:

  • Ending Cash Position: $5.3 Mil
  • GF Value™: $3.06 vs. price of $2.28 (25.5% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biote Business Description

Address 1875 W. Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
70GF Score

Get the complete analysis for BTMD

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.28
Price
$3.06
GF Value